New combo therapy aims to boost remission in tough rectal cancer

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years and ≤ 75 years. * Histologically confirmed colorectal adenocarcinoma with the lower margin of the lesion ≤ 10 cm from the anal verge as assessed by MRI, and immunohistochemistry confirming pMMR, or genetic testing demonstrating MSI-L or MSS. * Presence of at least one of the following high-risk factors as assessed by pelvic MRI: cT4a/b; N2; extramural vascular invasion (EMVI+); mesorectal fascia involvement (MRF+); enlarged lateral lymph node (longest diameter \> 7 mm). * Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1 * No prior surgery, radiotherapy, chemotherapy, or targeted therapy. * Able to tolerate radiotherapy, chemotherapy, and immunotherapy: ECOG performance status score 0-2. Laboratory results: white blood cell count ≥ 4.0 × 10⁹/L, platelet count ≥ 100 × 10⁹/L, hemoglobin ≥ 80 g/L, ALT \< 2 × ULN, total bilirubin \< 35 μmol/L, serum creatinine \< 1.5 × ULN or creatinine clearance ≥ 50 mL/min, thyroid-stimulating hormone within normal range (patients with stable thyroid function after hormone replacement therapy may be enrolled). * Willing to participate and able to provide written informed consent. Exclusion Criteria: * Presence of distant metastasis. * Patients with stage I or II rectal cancer who do not require preoperative neoadjuvant therapy. * Severe diseases involving the heart, lung, brain, kidney, gastrointestinal tract, or other systemic conditions. * Untreated chronic hepatitis B or HBV carriers with HBV DNA \> 500 IU/mL, or patients positive for HCV RNA. Patients with inactive hepatitis B surface antigen (HBsAg) carriers, those with hepatitis B who have been treated and are stable (HBV DNA \< 500 IU/mL), and those who have been cured of hepatitis C may be enrolled. * Active autoimmune disease or history of autoimmune disease with potential for relapse. * Receipt of corticosteroids (at a dose equivalent to prednisone \> 10 mg/day) or other immunosuppressive therapy within 2 weeks prior to study drug administration. * History of thyroid dysfunction. * Severe chronic or active infection requiring systemic antifungal or antiviral therapy, including tuberculosis infection. * History of allergic constitution or allergy to multiple drugs. * History of prior pelvic radiotherapy. * History of inflammatory bowel disease. * Unwillingness to participate or inability to provide written informed consent.